Medical Products Agency, Uppsala, Sweden.
Clin Pharmacokinet. 2012 Feb 1;51(2):69-76. doi: 10.2165/11596650-000000000-00000.
Modelling and simulation (M&S) of clinical data, e.g. pharmacokinetic, pharmacodynamic and clinical endpoints, is a useful approach for more efficient interpretation of collected data and for extrapolation of knowledge to the entire target population. This type of documentation is included in the majority of marketing authorization applications for new medicinal products. This article summarizes the current status of regulatory review with respect to the role of M&S in Europe from the perspective of the Swedish Medical Products Agency. At present, regulatory bodies in Europe encourage the application of the M&S approach during drug development. However, there is a lack of consensus and transparent guidance documents. The main regulatory usage is in the evaluation of dose choices in sub-populations and as support for the dosing regimen in general. The regulatory review of conestat alfa illustrates how the dose recommendation was revised during the approval procedure based on M&S information. A survey of marketing authorization applications for new medicinal products approved in 2010 revealed that the use of the information gained from M&S documentation varies with respect to both regulatory review and the applicants' presentation of the data in the submitted dossier. Increased utilization and broadened application of M&S is anticipated in pharmaceutical development, where one area of focus is medicines for paediatric patients. Accordingly, the regulatory agencies will need to increase their capability to assess and utilize this type of information, and an interactive process among regulatory agencies is warranted to provide more unified regulatory assessment and guidance. Moreover, applicants are encouraged to expand on the usage of exposure-response models to map the systemic exposure range that yields safe and efficacious treatment and to improve the presentation of the gained knowledge in summary documents of the marketing authorization applications.
临床数据(例如药代动力学、药效动力学和临床终点)的建模和模拟(M&S)是一种更有效地解释所收集数据和将知识外推至整个目标人群的有用方法。这种类型的文件包含在大多数新药物的营销授权申请中。本文从瑞典药品管理局的角度总结了欧洲监管审查中 M&S 的现状。目前,欧洲的监管机构鼓励在药物开发中应用 M&S 方法。然而,目前缺乏共识和透明的指导文件。主要的监管用途是在亚人群中评估剂量选择,并为一般剂量方案提供支持。康奈司他的监管审查说明了如何根据 M&S 信息在批准程序中修改剂量建议。对 2010 年批准的新药物营销授权申请的调查显示,M&S 文件中获得的信息的使用情况在监管审查和申请人在提交文件中呈现数据方面存在差异。在药物开发中,预计 M&S 的使用将增加,并得到更广泛的应用,其中一个重点领域是儿科患者的药物。因此,监管机构需要提高评估和利用此类信息的能力,监管机构之间需要进行互动,以提供更统一的监管评估和指导。此外,鼓励申请人扩大暴露-反应模型的使用,以映射产生安全有效的治疗的系统暴露范围,并改进营销授权申请总结文件中获得的知识的呈现方式。